EUVIMEDEUVIMED entdecken
Crossref

Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment

Gail A Edelsohn, Dominic Sisti

Perspectives in Biology and Medicine · 2023

DOI: 10.1353/pbm.2023.0007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Perspectives in Biology and Medicine, 2023. Verfasst von Gail A Edelsohn und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hallucinogens, Stress Disorders, Post-Traumatic. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent clinical trials of psychedelic drugs aim to treat a range of psychiatric conditions in adults. MDMA and psilocybin administered with psychotherapy have received FDA designation as "breakthrough therapies" for post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) respectively. Given the potential benefit for minors burdened with many of the same disorders, calls to expand experimentation to minors are inevitable. This essay examines psychedelic research conducted on children from 1959 to 1974, highlighting methodological and ethical flaws. It provides ethics and policy recommendations for psychedelics research involving children and adolescents, including recognizing that the psychedelic experience is an ineffable one that makes informed proxy consent for parents, guardians, and others especially challenging. Psychedelic experiences are associated with novel benefits and risks, such as significant personality changes, shifts in fundamental values, and possible re-exposure to traumatic memories. These effects may alter the process of personality development in minors. Recommendations for ethically sound psychedelics research in minors include strict adherence to eligibility criteria, including a comprehensive family and individual psychiatric, substance use, and trauma history. An age-appropriate assent process that includes considerations related to the use of therapeutic touch should be developed. In addition, oversight by data safety monitoring boards and patient and family advocates, coupled with the adoption of pharmacoequity best practices, will help to ensure safety and fairness of psychedelics research in children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensStress Disorders, Post-TraumaticHumansChildAdolescentPsilocybinInformed ConsentDepressive Disorder, Treatment-ResistantN-Methyl-3,4-methylenedioxyamphetamine

Substanzen

HallucinogensPsilocybinN-Methyl-3,4-methylenedioxyamphetamine

Zitieren

APA

Edelsohn, G. A., & Sisti, D. (2023). Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. Perspectives in Biology and Medicine. https://doi.org/10.1353/pbm.2023.0007

Vancouver

Edelsohn GA, Sisti D. Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. Perspectives in Biology and Medicine. 2023. doi:10.1353/pbm.2023.0007

BibTeX
@article{Edelsohn2023,
  author = {Edelsohn, Gail A and Sisti, Dominic},
  title = {Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment},
  journal = {Perspectives in Biology and Medicine},
  year = {2023},
  doi = {10.1353/pbm.2023.0007}
}
Kostenlos starten →